FOLH1 and neoplasm: Both radiopharmaceuticals showed satisfactory biodistribution profiles, especially CA012, with LNCaP-tumour accumulation at 1 h p.i. comparable to PSMA-617 (8.4 ± 3.7% ID/g) and a remarkably lower kidney uptake than PSMA-617 (5.1 ± 2.5% ID/g vs. 113.3 ± 24.4% ID/g).